Diagnostic Specialty Antibodies Market by Type (Primary, Secondary), Clonality (Monoclonal, Polyclonal), Technique (WB, Rapid Test, IHC, IP), Conjugate, and Application (Dengue, Malaria, Hepatitis, HIV, E. coli , Tuberculosis, Pneumonia, Cancer)- Forecast

Diagnostic Specialty Antibodies Market by Type (Primary, Secondary), Clonality (Monoclonal, Polyclonal), Technique (WB, Rapid Test, IHC, IP), Conjugate, and Application (Dengue, Malaria, Hepatitis, HIV, E. coli , Tuberculosis, Pneumonia, Cancer)- Forecast to 2029

Diagnostic Specialty Antibodies Market by Type (Primary, Secondary), Clonality (Monoclonal, Polyclonal), Technique (WB, Rapid Test, IHC, IP), Conjugate, and Application (Dengue, Malaria, Hepatitis, HIV, E. coli , Tuberculosis, Pneumonia, Cancer)- Forecast to 2029

The diagnostic specialty antibodies market is expected to grow at a CAGR of 4.6% from 2022–2029 to reach $39.99 billion by 2029.

Following a comprehensive primary and secondary research and an in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, challenges, and opportunities. The growth of the diagnostic specialty antibodies market is mainly attributed to the growing prevalence of diseases worldwide and the burden imposed on the people by these diseases, the rising incidences of unintended pregnancies, the increasing availability of funding for researchers with the use of diagnostic antibodies, and the increasing number of regulatory approvals of test kits containing diagnostic antibodies.

In addition to this, the high prevalence of diseases in emerging countries and the growing number of initiatives by public and private organizations supporting diagnosis activities to eradicate infectious diseases are expected to provide significant opportunities for the growth of this market during the forecast period.

Based on type, the market is segmented into primary antibodies and secondary antibodies. The primary antibodies segment is estimated to account for the largest share of the market in 2022. The capability of primary antibodies to easily bind to the target antigen is the key factor driving the demand for primary antibodies in the market. In addition, the mandatory requirement of primary antibodies in every assay and the regulatory approvals for primary antibody-based test kits have further promoted the growth of this segment.

Based on clonality, the market is segmented into monoclonal, polyclonal, and recombinant. The recombinant antibody segment is expected to witness the fastest CAGR during the forecast period. Recombinant antibodies can be produced in a shorter duration than other clonal antibodies. These antibodies are more cost-effective and offer a better affinity to bind to the target antigen. Moreover, recombinant antibodies eliminate the problems associated with hybridomas, which further contributes to its demand in the market.

Based on conjugate, the market is segmented into conjugated antibodies and unconjugated antibodies. The unconjugated antibodies segment is expected to witness the fastest growth rate during the forecast period. The high affinity and flexibility offered by unconjugated antibodies in assays is the key factor contributing to the growth of this segment. Also, the launch of unconjugated antibodies for disease diagnosis in the market further contributes to the growth of this segment.

Based on technique, the market is segmented into western blot, ELISA, lateral flow assay, immunohistochemistry, immunoprecipitation, immunocytochemistry, and others. The lateral flow assay segment is expected to grow at the fastest CAGR during the forecast period. The growing initiatives by public organizations promoting the usage of rapid test kits for improving the diagnosis rate are the key factors driving the demand for lateral flow assays in the market. Furthermore, lateral flow assays provide faster results than other techniques, such as western blot and IHC. Hence, these factors are expected to increase the demand for lateral flow assays in the market.

Based on application, the market is segmented into infectious diseases, oncology, pregnancy detection/fertility testing, and others. The oncology segment is estimated to register the fastest growth rate during the forecast period. The increase in the number of cancer screenings due to the rising incidences of cancer worldwide and the growing number of funding and investments for cancer diagnosis by various organizations are key factors contributing to the growth rate of this segment.

An in-depth analysis of the geographical scenario of the diagnostic specialty antibodies market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region.

North America is estimated to command the largest share of the diagnostic specialty antibodies market in 2022, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The increasing number of regulatory approvals and launches of antibodies and test kits containing diagnostic antibodies in the region and the high burden of infectious diseases and cancer are the major factors driving the growth of this market in North America. Moreover, the growing availability of research funding for diseases such as cancer, Alzheimer’s, and COVID-19 have further strengthened the market in the region.

Some of the key players operating in the global diagnostic antibody are Abcam plc (U.K.), F. Hoffman La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Creative Diagnostics (U.S.), Merck KGaA (Germany), Agilent Technologies, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Rockland Immunochemicals, Inc. (U.S.), Santa Cruz Biotechnology (U.S.), Novus Biologicals, LLC (U.S.), and Thermo Fisher Scientific Inc . (U.S.).

Scope of the Report:

Global Diagnostic Specialty Antibodies Market, by Type
Primary Antibodies
Secondary Antibodies

Global Diagnostic Specialty Antibodies Market, by Clonality

Monoclonal Antibodies
Polyclonal Antibodies
Recombinant Antibodies

Global Diagnostic Specialty Antibodies Market, by Technique

ELISA
Lateral Flow Assay
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Immunocytochemistry (ICC)
Other Techniques

Other techniques include immunofluorescence, flow cytometry, in situ hybridization, dot blot, radioimmunoassay, and others

Global Diagnostic Specialty Antibodies Market, by Conjugate

Conjugated Antibodies
Unconjugated Antibodies

Global Diagnostic Specialty Antibodies Market, by Application

Infectious Diseases
Respiratory Infections
COVID-19
Influenza
Tuberculosis (TB)
Pneumonia
Other Respiratory Infections
Parasitic Infections
Dengue
Malaria
Other Parasitic Infections
Gastrointestinal Infections (GI Infections)
Salmonellosis
E. Coli Infections
Other GI Infections
Blood Borne Diseases
Hepatitis
HIV
Other Blood Borne Infections
Other Infectious Diseases
Oncology
Pregnancy Detection/Fertility Testing
Other Applications

Note: Other parasitic infections include leishmaniasis and zika, among others

Other blood borne infections include syphilis, chlamydia, and gonorrhea, among others
Other GI infections include cholera, Helicobacter pylori (H. pylori), and campylobacteriosis, among others
Other respiratory infections include strep infections, pertussis, and respiratory syncytial virus (RSV), among others
Other infectious diseases include sepsis, rubella, impetigo, and others
Other applications include Alzheimer’s, autoimmune diseases and cardiac diseases, diabetes, and others

Global Diagnostic Specialty Antibodies Market, by Geography

North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe (RoE)
Asia-Pacific (APAC)
China
Japan
India
Rest of APAC (RoAPAC)
Latin America
Middle East & Africa